Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Staphylococcus aureus Glycerol-3-phosphate acyltransferase (plsY), partial CSB-YP753496SKV1
CSB-EP753496SKV1
CSB-BP753496SKV1
CSB-MP753496SKV1
CSB-EP753496SKV1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus LexA repressor (lexA) CSB-YP753497SKV
CSB-EP753497SKV
CSB-BP753497SKV
CSB-MP753497SKV
CSB-EP753497SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus DNA mismatch repair protein mutL (mutL), partial CSB-YP753498SKV
CSB-EP753498SKV
CSB-BP753498SKV
CSB-MP753498SKV
CSB-EP753498SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Ribonuclease J 2 (SAR1251), partial CSB-YP753499SKV
CSB-EP753499SKV
CSB-BP753499SKV
CSB-MP753499SKV
CSB-EP753499SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Ribosome maturation factor RimP (rimP) CSB-YP753500SKV
CSB-EP753500SKV
CSB-BP753500SKV
CSB-MP753500SKV
CSB-EP753500SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus GTP-sensing transcriptional pleiotropic repressor CodY (codY) CSB-YP753501SKV
CSB-EP753501SKV
CSB-BP753501SKV
CSB-MP753501SKV
CSB-EP753501SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Succinyl-CoA ligase [ADP-forming] subunit beta (sucC) CSB-YP753502SKV
CSB-EP753502SKV
CSB-BP753502SKV
CSB-MP753502SKV
CSB-EP753502SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Malonyl CoA-acyl carrier protein transacylase (fabD) CSB-YP753503SKV
CSB-EP753503SKV
CSB-BP753503SKV
CSB-MP753503SKV
CSB-EP753503SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Isoleucine--tRNA ligase (ileS), partial CSB-YP753504SKV
CSB-EP753504SKV
CSB-BP753504SKV
CSB-MP753504SKV
CSB-EP753504SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Cell division protein FtsZ (ftsZ) CSB-YP753505SKV
CSB-EP753505SKV
CSB-BP753505SKV
CSB-MP753505SKV
CSB-EP753505SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Phospho-N-acetylmuramoyl-pentapeptide-transferase (mraY), partial CSB-YP753506SKV
CSB-EP753506SKV
CSB-BP753506SKV
CSB-MP753506SKV
CSB-EP753506SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus UPF0747 protein SAR1153 (SAR1153), partial CSB-YP753507SKV
CSB-EP753507SKV
CSB-BP753507SKV
CSB-MP753507SKV
CSB-EP753507SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Heme-degrading monooxygenase isdG (isdG) CSB-YP753508SKV
CSB-EP753508SKV
CSB-BP753508SKV
CSB-MP753508SKV
CSB-EP753508SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Protoheme IX farnesyltransferase (ctaB), partial CSB-YP753509SKV
CSB-EP753509SKV
CSB-BP753509SKV
CSB-MP753509SKV
CSB-EP753509SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus UPF0223 protein SAR1071 (SAR1071) CSB-YP753510SKV
CSB-EP753510SKV
CSB-BP753510SKV
CSB-MP753510SKV
CSB-EP753510SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Peptide deformylase (def) CSB-YP753511SKV
CSB-EP753511SKV
CSB-BP753511SKV
CSB-MP753511SKV
CSB-EP753511SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Phosphocarrier protein HPr (ptsH) CSB-YP753512SKV
CSB-EP753512SKV
CSB-BP753512SKV
CSB-MP753512SKV
CSB-EP753512SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Phosphoribosylformylglycinamidine synthase 1 (purQ) CSB-YP753513SKV
CSB-EP753513SKV
CSB-BP753513SKV
CSB-MP753513SKV
CSB-EP753513SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Probable quinol oxidase subunit 4 (qoxD), partial CSB-YP753514SKV1
CSB-EP753514SKV1
CSB-BP753514SKV1
CSB-MP753514SKV1
CSB-EP753514SKV1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Staphostatin B (sspC) CSB-YP753515SKV
CSB-EP753515SKV
CSB-BP753515SKV
CSB-MP753515SKV
CSB-EP753515SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過(guò)多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過(guò)程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來(lái)自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來(lái)產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過(guò)多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過(guò)程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來(lái)選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見(jiàn)問(wèn)題。您可以單擊以下鏈接查看。http://m.cstxtech.com/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問(wèn),涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>